---
title: "如瑞迪博士实验室在加拿大推出了仿制的 Semaglutide 注射剂"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/286635919.md"
description: "药明康德已在加拿大推出其用于 2 型糖尿病的仿制 Semaglutide 注射剂，成为在获得加拿大卫生部合规通知后首批推出该产品的公司之一。该注射剂提供 2 毫克和 4 毫克的预填充笔，设计为每周使用一次。首席执行官 Erez Israeli 强调了公司致力于提供高质量 GLP-1 疗法并扩大全球市场准入的承诺"
datetime: "2026-05-15T22:23:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286635919.md)
  - [en](https://longbridge.com/en/news/286635919.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286635919.md)
---

# 如瑞迪博士实验室在加拿大推出了仿制的 Semaglutide 注射剂

Dr Reddy's Laboratories on Saturday said it has launched its generic version of Semaglutide injection used in treatment of type 2 diabetes in Canada.

The company is among the first firms to introduce a generic Semaglutide injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on April 28, 2026, Dr Reddy's said in a statement.

Canada is the first G7 country to grant market authorisation for Semaglutide injection, it added.

"The milestone highlights our readiness to serve the Canadian patients, supported by our deep expertise in complex drug and peptide development," Dr Reddy's CEO Erez Israeli said.

He further said:"With a well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality, and affordable GLP-1 therapies closer to patients." The Canada launch builds on the momentum of the company's recent launch in India under the brand name Obeda, Israeli said.

"As GLP-1 therapies continue to be a key focus area for us, we are actively working to expand access across multiple global markets," he noted.

In Canada, Dr Reddy's Semaglutide injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus, to improve glycemic control in combination with diet and exercise, the company said.

It is supplied as a sterile solution for subcutaneous injection in a pre-filled pen, available in 2 mg/pen and 4 mg/pen strengths, each delivering Semaglutide at a concentration of 1.34 mg/ml.

The 2 mg/pen is designed to deliver 0.25 mg or 0.5 mg doses, while the 4 mg/pen delivers 1 mg doses per injection, the statement said.

### 相关股票

- [RDY.US](https://longbridge.com/zh-CN/quote/RDY.US.md)

## 相关资讯与研究

- [如瑞迪博士在印度推出了针对 2 型糖尿病患者的口服药物 Obeda](https://longbridge.com/zh-CN/news/287073753.md)
- [如瑞迪博士在加拿大推出仿制药 Semaglutide，扩大 GLP-1 药物的推广](https://longbridge.com/zh-CN/news/286652907.md)
- [礼来 orforglipron 可帮助停止 GLP-1 注射剂的人群维持体重减轻效果](https://longbridge.com/zh-CN/news/286423020.md)
- [Cell Rep：破解 CAR-T 疗法失效之谜！患者 T 细胞 “衰老” 是罪魁祸首，新研究为精准筛选获益人群指明方向](https://longbridge.com/zh-CN/news/287171706.md)
- [从个性化疫苗到 “进化式 mRNA 疗法”：癌症疫苗如何追上肿瘤进化？](https://longbridge.com/zh-CN/news/286543229.md)